Lung Cancer Clinical Trials

and/or
83 Clinical Trials found
The purpose of this study is to see how well zipalertinib works to treat advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread. The cancer also has a mutation (change) in the EGFR gene. When people have an EGFR mutation, the EGFR protein on their cells can trigger cancer growth.
Researchers want to see if giving additional radiation therapy to standard treatment helps people with lung cancer to live longer. The people in this study have non-small cell lung cancer (NSCLC) that cannot be removed with surgery (inoperable cancer). The standard treatment includes image-guided radiation therapy (IGRT), chemotherapy, and immunotherapy with durvalumab. 
In addition, their cancers have a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive NSCLC.
Breast cancer and non-small cell lung cancer (NSCLC) can spread to the cerebrospinal fluid-filled space around the brain and spinal cord. This is called leptomeningeal metastasis (LM). The effects of LM on the nervous system can be very serious.
Researchers are comparing ivonescimab with pembrolizumab immunotherapy for the initial treatment of advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has metastasized (spread).
Researchers are doing this study to see if giving LY3537982 with standard lung cancer drugs is safe and works well. The people in this study have non-small cell lung cancer that has spread. In addition, their cancers have a gene mutation (change) called KRASG12C, which can cause cancer cells to grow.
In addition, their cancers have a mutation (change) in the G12C location of the KRAS gene. Olomorasib may help slow or stop the growth of cancers with KRAS G12C mutations. It is taken orally (by mouth).
Researchers are comparing RMC-6236 with docetaxel for the treatment of lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread beyond its original location. In addition, their tumors have a mutation (change) in the RAS gene.
Researchers are comparing taletrectinib with a placebo (inactive drug) in people with non-small cell lung cancer (NSCLC). The people in this study have stage 1B-3A NSCLC that has a ROS1 gene fusion. They have had the tumor completely removed with surgery.